Liu Ying, Xiong Lei, Cai Ruoxue, Chen Yue, Ye Jinjun, Shen Bo, Zhou Guoren
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China.
General Hospital of Eastern Theater Command, Nanjing 210002, China.
Zhongguo Fei Ai Za Zhi. 2023 Aug 20;26(8):615-620. doi: 10.3779/j.issn.1009-3419.2023.101.23.
Lung cancer is the leading cause of cancer death, and non-small cell lung cancer (NSCLC) accounts for 85%. Immunotherapy has significantly improved the clinical prognosis of patients with NSCLC. However, because of the complexity and heterogeneousness of the tumor microenvironment, only a subset of individuals can benefit from immunotherapy. Therefore, it is necessary to explore effective predictive biomarkers for immunotherapy of NSCLC. Tertiary lymphoid structure (TLS) is an ectopic lymphoid organ that is highly similar to secondary lymphoid organs (SLO), and the presence of TLS has been found to be closely associated with a good prognosis in immunotherapy for a variety of solid tumors, including NSCLC. This article provides a review of the prognostic role of tertiary lymphoid structures in immunotherapy of NSCLC, in order to offer references for screening suitable candidates for immunotherapy of NSCLC and develop personalized and precise treatment plans. .
肺癌是癌症死亡的主要原因，其中非小细胞肺癌（NSCLC）占85%。免疫疗法显著改善了NSCLC患者的临床预后。然而，由于肿瘤微环境的复杂性和异质性，只有一部分个体能从免疫疗法中获益。因此，有必要探索NSCLC免疫治疗的有效预测生物标志物。三级淋巴结构（TLS）是一种与二级淋巴器官（SLO）高度相似的异位淋巴器官，并且已发现TLS的存在与包括NSCLC在内的多种实体瘤免疫治疗的良好预后密切相关。本文综述了三级淋巴结构在NSCLC免疫治疗中的预后作用，以便为筛选NSCLC免疫治疗的合适候选者及制定个性化精准治疗方案提供参考。
